Lebeau Paul F, Platko Khrystyna, Byun Jae Hyun, Makda Yumna, Austin Richard C
Department of Medicine, Division of Nephrology, Institute of St. Joe's Hamilton, The Hamilton Center for Kidney Research, McMaster University, Hamilton, ON L8N 4A6, Canada.
Metabolites. 2022 Feb 26;12(3):215. doi: 10.3390/metabo12030215.
The importance of the proprotein convertase subtilisin/kexin type-9 () gene was quickly recognized by the scientific community as the third locus for familial hypercholesterolemia. By promoting the degradation of the low-density lipoprotein receptor (LDLR), secreted PCSK9 protein plays a vital role in the regulation of circulating cholesterol levels and cardiovascular disease risk. For this reason, the majority of published works have focused on the secreted form of PCSK9 since its initial characterization in 2003. In recent years, however, PCSK9 has been shown to play roles in a variety of cellular pathways and disease contexts in LDLR-dependent and -independent manners. This article examines the current body of literature that uncovers the intracellular and LDLR-independent roles of PCSK9 and also explores the many downstream implications in metabolic diseases.
前蛋白转化酶枯草溶菌素/克新9型(PCSK9)基因的重要性很快被科学界认可为家族性高胆固醇血症的第三个基因位点。通过促进低密度脂蛋白受体(LDLR)的降解,分泌的PCSK9蛋白在循环胆固醇水平调节和心血管疾病风险中起着至关重要的作用。因此,自2003年首次被鉴定以来,大多数已发表的研究都集中在PCSK9的分泌形式上。然而,近年来,PCSK9已被证明以依赖和不依赖LDLR的方式在多种细胞途径和疾病背景中发挥作用。本文审视了当前揭示PCSK9细胞内及不依赖LDLR作用的文献,并探讨了其在代谢性疾病中的诸多下游影响。